Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis [0.03%]
恩拉卡帕韦相关的药物耐药性：对扩大长效HIV暴露前预防的影响
Gert van Zyl,Mateo Prochazka,Heather-Marie Ann Schmidt et al.
Gert van Zyl et al.
Although drug resistance could emerge if lenacapavir is initiated during undiagnosed acute infection or if infection occurs during the drug's pharmacokinetic tail, these cases will not compromise the effectiveness of WHO-recommended therapi...
Do we need routine integrase resistance testing before starting antiretroviral therapy? [0.03%]
初治患者启动抗病毒治疗前需要进行整合酶耐药检测吗？
Rami Kantor,Alice K Pau,Michael J Kozal et al.
Rami Kantor et al.
Oral second-generation integrase strand transfer inhibitors are now anchor drugs of antiretroviral therapy (ART) globally due to their high resistance barriers. In high-income settings, guidelines recommend routine protease and reverse tran...
Jirair Ratevosian,Michael Reid,Zhao Ni et al.
Jirair Ratevosian et al.
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial [0.03%]
多替拉韦和拉米夫定与比克特拉韦、恩曲他滨和替诺福韦阿拉芬酰胺治疗HIV感染患者的维持疗法：PASO-DOBLE随机、多中心、开放标签非劣效性试验的48周结果
Pablo Ryan,José L Blanco,Mar Masia et al.
Pablo Ryan et al.
Background: Although single-tablet, oral bictegravir, emtricitabine, and tenofovir alafenamide or dolutegravir and lamivudine are preferred regimens in several major guidelines and are widely used in many countries, they ...
Jennifer Manne-Goehler,Nomathemba Chandiwana
Jennifer Manne-Goehler
Marco Vitoria,Graeme Meintjes,Nathan Ford et al.
Marco Vitoria et al.
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis [0.03%]
REPRIEVE试验中抗逆转录病毒药物对主要不良心血管事件的影响：纵向队列分析
Carl J Fichtenbaum,Carlos D Malvestutto,Maya G Watanabe et al.
Carl J Fichtenbaum et al.
Background: In the REPRIEVE trial of statin therapy in people with HIV, pitavastatin reduced major adverse cardiovascular events (MACE) among those with low-to-moderate risk of cardiovascular disease (CVD). We aimed to in...